This newsletter aims to provide a central hub for information, milestones, and updates regarding the COVID Treatment QuickStart Consortium.
The COVID Treatment QuickStart Consortium partners with governments to rapidly introduce and scale access to COVID-19 oral antiviral therapies in vulnerable and high-risk populations presenting with mild to moderate symptoms within five days of symptom onset through a public health test-and-treat model. QuickStart’s top priorities are:
- Ensuring treatments are accessible in all parts of the world;
- Preparing for potential future COVID-19 surges; and
- Building primary healthcare capacity for test-and-treat beyond COVID-19.